Clinical Study on the Combination of Tanreqing Injection Nebulized Inhalation and Levofloxacin in the Treatment of Elderly Patients with Respiratory Tract Infections
Objective:To investigate the clinical efficacy and safety of Tanreqing injection combined with levofloxacin in the treatment of elderly patients with respiratory tract infection.Methods:104 patients with respiratory tract infection admitted to a hospital between June 2022 and June 2023 were assigned into the control group and the observation group by random number table method,with 52 patients each.Both groups received standard treatments including oxygen support,cough expectorants,correction of water and electrolyte imbalances.The control group received levofloxacin hydrochloride injection,while the observation group received Tanreqing injection via atomized inhalation based on the control group.Both groups underwent continuous treatment for a week.Serum levels of inflammatory factors[interferon-γ(IFN-γ),interleukin-4(IL-4),interleukin-5(IL-5),tumor necrosis factor-α(TNF-α)]and acute protein markers[serum amyloid A(SAA),C reactive protein(CRP)]and the incidence of adverse reactions were compared between the two groups.Results:Following treatment,serum levels of IFN-γ,IL-4,IL-5,and TNF-α decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).Serum levels of SAA and CRP decreased in both groups(P<0.05),with the observation group exhibiting lower levels than the control group(P<0.05).The total incidence of adverse reactions such as nausea,vomiting,loss of appetite,redness at the injection site and rash in the observation group(5.77%)was lower than that in the control group(15.38%,P<0.05).Conclusion:The combination of Tanreqing injection with levofloxacin in the treatment of respiratory tract infection,on the basis of conventional therapy,effectively reduces patients'inflammatory response,lowers acute protein marker levels,and does not elevate the risk of adverse reactions.
万方数据
维普
